future of glp 1 drugs Are GLP-1 weight-loss quietly reshaping how people eat? Could reduced appetite and smaller portion sizes change the food innovation? And what does this shift mean for the growing role GLP-1 Market Trends and Global

Overall, the GLP-1 market is expected to experience annual growth exceeding 20% and will hit $133 billion worldwide by 2030, according to a MarketWatch report from February

In 2021, Wegovy ( semaglutide) became the other GLP-1 approved for weight loss, although its lower-dose sibling Ozempic was approved for diabetes in 2017

Check out the product HERE

Athletic performance & recovery One of the most recognized l-carnitine benefits is its potential support for exercise performance

For example, both semaglutide and tirzepatide, in addition to their primary indications for type 2 diabetes and obesity, have demonstrated cardiovascular benefits